Personalized Lung Cancer Screening Tool Adds Asbestos Exposure

A University of Michigan and Veterans Affairs research team has developed a novel, personalized lung cancer screening tool that accounts for past asbestos exposure. Asbestos exposure is best known as the primary cause of mesothelioma, but it also significantly increases the chance of developing lung cancer. Adding asbestos to the lung-cancer screening tool also should help identify mesothelioma in its earliest stages, when it is most treatable. Mesothelioma is not usually diagnosed until it has progressed into stage 3 or stage 4, when treatment is more palliative than potentially curative. The tool is designed to better identify people who may benefit — and who won’t benefit — from low dose computed tomography (CT) screening for lung cancer. Early CT screening has become more popular in recent years, leading to a reduction in lung cancer mortality, yet it remains a controversial topic. More than 200,000 Americans are diagnosed with lung cancer each year, and it remains the leading cause of cancer death in the United States. Personalizing Lung Cancer Screening The innovative screening tool stems from a study the team published May 29 in the Annals of Internal Medicine. It details best practices for doctors to personalize lung cancer screening decisions for each patient. The study explores individual lung cancer risks along with potential benefits. It also explores patient attitudes concerning problems and consequences that could arise with screening. “...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Image-based response assessment is often used as a surrogate for the efficacy of a treatment in patients. The radiological response assessment in patients with malignant pleural mesothelioma (MPM) is notoriously difficult, despite changes in the scoring system, modified Response Evaluation Criteria in Solid Tumors (modified RECIST). The current clinical method for tumor response assessment in mesothelioma is the modified RECIST guideline, which calls for two linear measurements of tumor thickness to be summed from each of three axial sections, primarily in computed tomography (CT) scans.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Although malignant mesothelioma (MM) is rare among thoracic malignancies, approximately 1500 and 3000 patients are newly diagnosed each year in Japan and the United States [1], respectively. Treatment of MM, including surgery, radiotherapy, and chemotherapy, is recommended according to stage, performance status, pulmonary function, complications, and patient preference. First-line chemotherapy for advanced MM involves a combination of cisplatin and pemetrexed as the standard treatment. Although this combination has been proven to prolong survival over cisplatin alone in a phase III trial (12.1 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to assess physical function and HRQOL of MPM patients following pleurectomy/decortication (P/D) in the convalescent phase.MethodsThe study included 16 male MPM patients who underwent P/D between September 2014 and August 2016. Physical function was assessed based on handgrip and knee extensor strengths, the six-minute walk distance (6MWD), and pulmonary function, including forced vital capacity (FVC) and forced expiratory volume in one second (FEV1). HRQOL was assessed using the Medical Outcome Study 36-item Short Form Health Survey (SF-36). The assessment was performed preoperatively, postoperatively, and...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Authors: Sano M, Kaneko MK, Kato Y Abstract The highly O-glycosylated membrane glycoprotein podoplanin (PDPN) is frequently overexpressed in several malignant cancers, such as oral cancer, lung cancer, germinal neoplasia, mesothelioma, and brain tumor. The expression of PDPN is strongly associated with cancer progression and poor prognosis. PDPN possesses three tandem repeats of platelet aggregation-stimulating (PLAG) domains (PLAG1, PLAG2, and PLAG3) and PLAG-like domain (PLD), and binds to C-type lectin-like receptor 2 (CLEC-2) on platelets, followed by PDPN-mediated platelet aggregation. We have previously estab...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A new 33-patient case study published in the Journal of Occupational and Environmental Medicine provides some of the strongest proof yet that exposure to asbestos-tainted talcum powder may cause malignant mesothelioma, a rare and deadly cancer that affects tissues lining internal organs. This isn’t only an important scientific discovery—it could also give new ammunition to plaintiffs in the thousands of cases brought against brands selling talcum-powder-based products alleged to cause cancer, like Johnson &Johnson’s Baby Powder. “It’s very, very hard, in general, to prove exactly what caus...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Environmental Health HealthSummit19 Research toxins Source Type: news
This study aimed to investigate the feasibility of fitting dual-input tracer kinetic models to DCE-MRI datasets of thoracic malignancies, including malignant pleural mesothelioma (MPM) and nonsmall cell lung cancer (NSCLC), by comparing them to single-input (pulmonary or systemic arterial input) tracer kinetic models for the voxel-level analysis within the tumor with respect to goodness-of-fit statistics. Fifteen patients (five MPM, ten NSCLC) underwent DCE-MRI prior to radiotherapy. DCE-MRI data were analyzed using five different single- or dual-input tracer kinetic models: Tofts-Kety (TK), extended TK (ETK), two compartm...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A mesothelioma patient at West Cancer Center in Memphis, Tennessee, is the first in the country to use NovoTTF-100L, a noninvasive electric therapy treatment, since its approval by the U.S. Food and Drug Administration in May. The FDA’s approval of Novocure’s Tumor Treating Fields device for the treatment of mesothelioma marked the first new FDA-approved treatment option for the rare asbestos-related cancer in more than 15 years. NovoTTF-100L uses a low-voltage electrical field that is distributed with three pads attached to the front and back of a person’s chest. The electrical current is designed to di...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractBackgroundNY-ESO-1 and LAGE-1a are antigens expressed in several tumours, including non-small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells directed against NY-ESO-1/LAGE-1a have shown objective responses between 40% and 60% in synovial sarcoma, metastatic melanoma and multiple myeloma. Pembrolizumab (PEM) is a monoclonal antibody that blocks PD-1/PD-L1 interaction and increases anti-tumour activity in anti-tumour T cells. Here, PEM will be used in combination with NY-ESO-1/LAGE-1a T-cell receptor engineered patient T cells (GSK3377794) to potentially improve clinical benefit in this p...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | CT Scan | Environmental Health | Internal Medicine | Learning | Lung Cancer | Mesothelioma | Palliative | PET Scan | Smokers | Study | Universities & Medical Training | USA Health